chr5-80675095-C-CA
Position:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_002439.5(MSH3):c.1148dupA(p.Asn385fs) variant causes a frameshift change. The variant allele was found at a frequency of 0.00000754 in 1,459,408 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: not found (cov: 32)
Exomes 𝑓: 0.0000075 ( 0 hom. )
Consequence
MSH3
NM_002439.5 frameshift
NM_002439.5 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 4.41
Genes affected
MSH3 (HGNC:7326): (mutS homolog 3) The protein encoded by this gene forms a heterodimer with MSH2 to form MutS beta, part of the post-replicative DNA mismatch repair system. MutS beta initiates mismatch repair by binding to a mismatch and then forming a complex with MutL alpha heterodimer. This gene contains a polymorphic 9 bp tandem repeat sequence in the first exon. The repeat is present 6 times in the reference genome sequence and 3-7 repeats have been reported. Defects in this gene are a cause of susceptibility to endometrial cancer. [provided by RefSeq, Mar 2011]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PP5
Variant 5-80675095-C-CA is Pathogenic according to our data. Variant chr5-80675095-C-CA is described in ClinVar as [Likely_pathogenic]. Clinvar id is 643621.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MSH3 | NM_002439.5 | c.1148dupA | p.Asn385fs | frameshift_variant | 7/24 | ENST00000265081.7 | NP_002430.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MSH3 | ENST00000265081.7 | c.1148dupA | p.Asn385fs | frameshift_variant | 7/24 | 1 | NM_002439.5 | ENSP00000265081.6 | ||
MSH3 | ENST00000658259.1 | c.980dupA | p.Asn329fs | frameshift_variant | 7/24 | ENSP00000499617.1 | ||||
MSH3 | ENST00000667069.1 | c.1148dupA | p.Asn385fs | frameshift_variant | 7/22 | ENSP00000499502.1 | ||||
MSH3 | ENST00000670357.1 | n.1148dupA | non_coding_transcript_exon_variant | 7/25 | ENSP00000499791.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome AF: 0.00000754 AC: 11AN: 1459408Hom.: 0 Cov.: 31 AF XY: 0.00000964 AC XY: 7AN XY: 726118
GnomAD4 exome
AF:
AC:
11
AN:
1459408
Hom.:
Cov.:
31
AF XY:
AC XY:
7
AN XY:
726118
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
Bravo
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2023 | MSH3: PVS1, PM2 - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 24, 2023 | This sequence change creates a premature translational stop signal (p.Asn385Glnfs*19) in the MSH3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH3 are known to be pathogenic (PMID: 27476653, 37402566). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with MSH3-related conditions. ClinVar contains an entry for this variant (Variation ID: 643621). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Oct 09, 2024 | The MSH3 c.1148dup (p.Asn385Glnfs*19) variant alters the translational reading frame of the MSH3 mRNA and is predicted to cause the premature termination of MSH3 protein synthesis. This variant has not been reported in individuals with MSH3-related conditions in the published literature. The frequency of this variant in the general population, 0.000004 (1/248208 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Based on the available information, this variant is classified as likely pathogenic. - |
Familial adenomatous polyposis 4 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Aug 29, 2023 | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 17, 2023 | The c.1148dupA pathogenic mutation, located in coding exon 7 of the MSH3 gene, results from a duplication of A at nucleotide position 1148, causing a translational frameshift with a predicted alternate stop codon (p.N385Qfs*19). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Endometrial carcinoma;C4310719:Familial adenomatous polyposis 4 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 26, 2024 | - - |
Endometrial carcinoma Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 17, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at